Pan-cancer analysis reveals tumor-associated macrophage communication in the tumor microenvironment

Table 1 Results of immune function quality of host in different groups

Item	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5	Patient 6	Patient 7	Patient 8	Patient 9	Patient 10	Patient 11	Patient 12
ZLBXB-FZ1	16.98	22.61	17.63	25.23	21.52	21.41	17.68	22.34	25.52	21.75	18.74	38.12
CD3+	69.73	85.58	79.45	80.23	72.56	68.23	87.66	82.77	75.69	75.27	84.53	64.75
CD3+CD4+CD8−	36.12	58.29	55.61	47.41	38.89	34.15	56.12	51.92	46.82	31.20	56.21	46.31
CD3+CD4−CD8+	29.27	26.41	28.63	32.61	32.77	29.53	26.31	26.23	31.63	34.22	23.23	19.43
CD4+CD8+	1.01	1.22	0.46	1.72	1.09	0.73	1.87	0.57	1.80	0.80	1.68	0.21
CD4−CD8−	6.07	4.84	2.43	2.81	10.65	5.01	4.16	2.69	3.88	10.93	4.63	2.65
CD3−CD19+	12.71	3.82	3.77	3.10	3.98	15.74	3.08	4.52	2.98	4.56	3.84	14.23
CD3−CD16/56+	15.82	14.26	13.91	13.15	22.91	14.47	13.72	10.23	17.22	21.71	13.81	13.51
CD3+CD16/56+	6.23	7.92	5.61	3.88	6.98	6.23	7.68	5.88	3.62	7.30	7.41	0.88
High or low flag	L	L	L	L	L	L	L	L	L	L	L	H

Item	Patient 13	Patient 14	Patient 15	Patient 16	Patient 17	Patient 18	Patient 19	Patient 20	Patient 21	Patient 22	Patient 23	Reference range
ZLBXB-FZ1	19.17	42.73	34.01	38.54	22.76	37.18	16.99	42.66	38.41	32.31	22.54	27.90–37.30
CD3+	58.26	68.27	66.09	75.29	73.90	69.12	60.31	66.86	70.31	76.44	73.52	26.00–76.80
CD3+CD4+CD8−	49.27	42.98	46.58	45.87	46.88	46.21	44.32	41.42	40.21	48.64	44.63	30.00–46.00
CD3+CD4−CD8+	16.72	22.79	26.88	24.76	26.18	20.34	14.11	29.31	25.87	27.17	24.61	19.20–33.60
CD4+CD8+	0.77	2.81	0.66	0.62	0.62	0.80	0.77	2.80	0.60	0.19	0.77	0.00–2.00
CD4−CD8−	1.54	1.62	1.45	2.87	1.34	3.21	1.45	1.29	1.33	3.21	2.53	0.00–12.00
CD3−CD19+	27.81	14.29	26.41	15.31	15.23	19.26	26.42	13.14	28.61	14.31	12.95	8.50–14.50
CD3−CD16/56+	14.89	14.61	9.31	9.18	9.14	10.41	13.21	15.34	7.63	7.58	12.13	9.50–23.50
CD3+CD16/56+	1.35	4.78	6.79	3.89	2.11	0.88	2.11	4.77	6.23	3.22	1.51	–
High or low flag	H	H	H	H	H	H	H	H	H	H	H	–

ISSN: 2162-3619